Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of BG00012 (dimethyl fumarate) on lymphocyte subsets in relapsing-remitting multiple sclerosis
2015-001973-42Phase 3Completed
- Sponsor
- Biogen
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of dimethyl fumarate in multiple sclerosis (MS), sponsored by Biogen. Primary endpoint: Change in lymphocyte subset counts. Started Nov 2015; status: completed.
02
Drugs
dimethyl fumarate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2015-001973-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001973-42.